SEC Form 3 filed by InMode Ltd.
$INMD
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/29/2025 | Buy → Neutral | BTIG Research | |
| 4/28/2025 | $22.00 → $16.00 | Outperform → Neutral | Robert W. Baird |
| 10/17/2024 | $25.00 | Buy | BTIG Research |
| 7/23/2024 | $21.00 → $19.00 | Buy → Hold | Jefferies |
| 11/3/2023 | $52.00 → $24.00 | Buy → Neutral | UBS |
| 10/13/2023 | $55.00 → $22.00 | Buy → Hold | Canaccord Genuity |
| 3/29/2023 | $40.00 | Buy | UBS |
| 2/17/2023 | Buy → Hold | Needham |
Conexeu Sciences just 3D-bioprinted a new tissue matrix to one of the most respected regenerative medicine institutes in the world. For investors watching how breast reconstruction — and the wider field of tissue regeneration — evolves, the next 18 months matter. NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary — For more than fifty years, breast reconstruction has mostly meant one thing: replacement. A silicone shell, filled with gel, designed to restore shape and volume, none of them designed to regenerate the breast's own living tissue. That gap has consequences. Roughly two-thirds of the more than 100,000 women in the United States who undergo a mastectomy ea
YOKNEAM, Israel, May 20, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode" or the "Company"), a leading global provider of innovative medical technologies, today announced the appointment of Dr. Shlomo Nass as Chairman of the Company's Board of Directors (the "Board") and Moshik Itzkovich as Chief Financial Officer, effective immediately. Dr. Nass succeeds Dr. Michael Anghel, who retired earlier this month, and will lead the Board in supporting the Company's long-term strategic growth and governance priorities. Dr. Nass brings decades of expertise in corporate law, accoun
YOKNEAM, Israel, May 13, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences and events: Barclays Virtual West Coast Bus TripPresenters: Yair Malca, Outgoing Chief Financial Officer and Moshik Itzkovich, Senior VP of FinanceFormat: Virtual investor bus tourWhen: Wednesday, May 20Jefferies Global Healthcare ConferencePresenters: Yair Malca, Outgoing Chief Financial Officer and Moshik Itzkovich, Senior VP of FinanceFormat: In-person fireside chat moderated by Matt Taylor, Senior Equity Analyst and one-on-one meetingsWhen: Wednesday, June 3, fireside chat at 12:45 p
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
SC 13G/A - InMode Ltd. (0001742692) (Subject)
SC 13G/A - InMode Ltd. (0001742692) (Subject)
SC 13G - InMode Ltd. (0001742692) (Subject)
3 - InMode Ltd. (0001742692) (Issuer)
3 - InMode Ltd. (0001742692) (Issuer)
3 - InMode Ltd. (0001742692) (Issuer)
BTIG Research downgraded InMode from Buy to Neutral
Robert W. Baird downgraded InMode from Outperform to Neutral and set a new price target of $16.00 from $22.00 previously
BTIG Research initiated coverage of InMode with a rating of Buy and set a new price target of $25.00
Conexeu Sciences just 3D-bioprinted a new tissue matrix to one of the most respected regenerative medicine institutes in the world. For investors watching how breast reconstruction — and the wider field of tissue regeneration — evolves, the next 18 months matter. NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary — For more than fifty years, breast reconstruction has mostly meant one thing: replacement. A silicone shell, filled with gel, designed to restore shape and volume, none of them designed to regenerate the breast's own living tissue. That gap has consequences. Roughly two-thirds of the more than 100,000 women in the United States who undergo a mastectomy ea
YOKNEAM, Israel, May 20, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode" or the "Company"), a leading global provider of innovative medical technologies, today announced the appointment of Dr. Shlomo Nass as Chairman of the Company's Board of Directors (the "Board") and Moshik Itzkovich as Chief Financial Officer, effective immediately. Dr. Nass succeeds Dr. Michael Anghel, who retired earlier this month, and will lead the Board in supporting the Company's long-term strategic growth and governance priorities. Dr. Nass brings decades of expertise in corporate law, accoun
IRVINE, Calif., Nov. 3, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, has appointed Michael Dennison, most recently Vice President of Sales, as President of North America. Dennison has held nearly every sales position in the aesthetic medical device industry, consistently producing at the highest level in each. With close to a decade of leadership experience at InMode, Dennison has advanced through roles from District Sales Manager to Vice President of Sales, driving national revenue growth, expanding market shar
YOKNEAM, Israel, May 6, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the first quarter of 2026. First Quarter 2026 Highlights:● Quarterly GAAP revenues of $82.0 million, compared to $77.9 million in the first quarter of 2025.● Quarterly revenues from consumables and service of $21.4 million, an increase of 6% compared to the first quarter of 2025.● GAAP operating income of $10.1 million, *non-GAAP operating income of $14.0 million.● Total cash po
Conference call to be held on Wednesday, May 6, 2026, at 8:30 a.m. Eastern TimeYOKNEAM, Israel, April 13, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the first quarter of 2026 before the Nasdaq market opens on Wednesday, May 6, 2026. InMode is currently finalizing its financial results for the first quarter of 2026. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of I
YOKNEAM, Israel, Feb. 10, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the fourth quarter and full year of 2025. Fourth Quarter 2025 Highlights: Quarterly GAAP revenues of $103.9 million, compared to $97.9 million in the fourth quarter of 2024.Quarterly revenues from consumables and service of $21.5 million, an increase of 8% compared to the fourth quarter of 2024.GAAP operation income of $26 million, *non-GAAP operation income of $28.5 million.Total cash position of $555.3 million as of December 31, 2025, including cash and cash equivalents, marketable securiti